As of November 7, 2026, Pacific Biosciences of California, Inc. is a publicly traded company (Nasdaq: PACB); its largest reported holder is T. Rowe Price, with 10.8% on Schedule 13G of November 6, 2026, then ARK Invest (9.59%). The largest insider holding is Christian O. Henry with 3,581,813 shares (1.1% of shares outstanding), per Form 4 of March 4, 2026 (Schedule 13G, November 6, 2026).
Is this your company?
About to sign with, pay or invest in Pacific Biosciences of California, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Pacific Biosciences of California, Inc. a real, registered company?
- Pacific Biosciences Of Calif files with the SEC under CIK 1299130 (its SEC filings).
- Its shares are listed under the ticker PACB on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Menlo Park, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under PACIFIC BIOSCIENCES OF CALIFORNIA, INC. in our court records and SEC 8-K records (as of 2026-11-07).
- Layoffs: 1 exit or restructuring plan reported on Form 8-K, Item 2.05 (latest filed 2026-08-05, about 40 jobs).
- Leadership changes: the latest reported is Bill Meyer, Chief Accounting Officer (Form 8-K filed 2026-11-04). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names T. Rowe Price (filed 2026-11-06).
Who are Pacific Biosciences of California, Inc.'s owners and officers?
Pacific Biosciences of California, Inc.: incorporated in Delaware; business address in Menlo Park, California; industry Laboratory Analytical Instruments (Schedule 13G, 2026-11-06).
Officers and directors, each with the role and the filing that names them:
- : Director (Form D, 2023-10-19)
- : Director (Form D, 2023-10-19)
- : Executive Officer, Director (Form D, 2023-10-19)
- : Director (Form D, 2023-10-19)
- : Director (Form D, 2023-10-19)
- : Director (Form D, 2023-10-19)
- : Director (Form D, 2023-10-19)
- : Director (Form D, 2023-10-19)
- : Director (Form D, 2023-10-19)
- : Executive Officer (Form D, 2023-10-19)
- : Executive Officer (Form D, 2023-10-19)
- : Executive Officer (Form D, 2023-10-19)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-11-06 | T. Rowe Price Associates, Inc. | 10.8% |
| Schedule 13G/A, 2026-08-14 | Ark Investment Management LLC | 9.59% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-03 | Ark Investment Management LLC | 12.34% |
| Schedule 13G/A, 2025-11-14 | Gregory Boyd Penner | 2.8% |
| Schedule 13G/A, 2025-11-04 | Ark Investment Management LLC | 10.3% |
| Schedule 13G/A, 2025-08-13 | Gregory Boyd Penner | 6.8% |
| Schedule 13G/A, 2025-07-24 | Edmond De Rothschild Asset Management (France) | 4.5% |
Questions about who owns Pacific Biosciences of California, Inc.
Who owns Pacific Biosciences of California, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Pacific Biosciences of California, Inc.: T. Rowe Price Associates, Inc. (10.8%, Schedule 13G, filed 2026-11-06) and Ark Investment Management LLC (9.59%, Schedule 13G/A, filed 2026-08-14).
Who are the largest shareholders of Pacific Biosciences of California, Inc.?
By the share each holder's latest filing reports, the largest holders of Pacific Biosciences of California, Inc. on this page are T. Rowe Price Associates, Inc. (10.8%) and Ark Investment Management LLC (9.59%).
When did T. Rowe Price Associates, Inc. buy into Pacific Biosciences of California, Inc.?
The filings give report dates, not purchase dates. The earliest filing from T. Rowe Price Associates, Inc. on this page is the Schedule 13G, filed 2026-11-06, reporting 10.8%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Pacific Biosciences of California, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Pacific Biosciences of California, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Pacific Biosciences of California, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-11-04 | Bill Meyer | Chief Accounting Officer | appointed | |
| Form 8-K, 2026-07-09 | Christopher M. Smith | Director | departed |
Which insiders own Pacific Biosciences of California, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Christian O. Henry: 3,581,813 shares (1.1% of shares outstanding) (Form 4, 2026-03-04).
- Mark Van Oene: 2,705,853 shares (0.86% of shares outstanding) (Form 4, 2026-08-18).
- James R. Gibson II: 1,083,848 shares (0.35% of shares outstanding) (Form 4, 2026-10-08).
- Susan Kim: 695,654 shares (0.22% of shares outstanding) (Form 4, 2024-10-02).
- Michele Farmer: 305,948 shares (0.10% of shares outstanding) (Form 4, 2026-03-04).
Shares outstanding: 312,926,730 as of 2026-10-31, from the company's latest SEC cover page.
How much has Pacific Biosciences of California, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2023-10-19 | $84.76M | $84.76M |
| Form D, 2023-08-17 | $85M | $85M |
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-02-02).
Red flags found
1 exit or restructuring plan on Form 8-K (latest Form 8-K, 2026-08-05).
Keep reading
More on Pacific Biosciences of California, Inc. and the records around it.
Pacific Biosciences of California, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Leadership changes Aug 2026
- Layoff notices Aug 2026
Companies that share a holder
- EDMOND DE ROTHSCHILD ASSET MANAGEMENT (FRANCE) also filed stake reports on 1 other company: ZipRecruiter, Inc. (Apr 2026)
- ARK Investment Management LLC also filed stake reports on 20 other companies: Tempus AI, Inc. (Nov 2026), 10x Genomics, Inc. (Oct 2026), Twist Bioscience Corp (Sep 2026)
- T. Rowe Price Associates, Inc. also filed stake reports on 191 other companies: APARTMENT INVT & MGMT CO -A (Oct 2026), BETA BIONICS INC (Oct 2026), 10X GENOMICS INC-CLASS A (Sep 2026)
Related pages
LayoffsLeadership changes5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/pacific-biosciences-of-calif